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Objective: If the geometric distortion during dilated heart failure could be corrected,
the tension on the myocytes would be decreased, thereby leading to an improvement
in left ventricular systolic function. We tested the effects of the CardioClasp
(CardioClasp Inc, Pine Brook, NJ), a left ventricular reshaping device, on the failing
heart, and our empirical data were compared with computationally derived data.
Methods: Heart failure was induced by 4-week rapid cardiac pacing. At the terminal
experiment, an isolated failing heart preparation (isovolumic contraction, n  5) or
an intact failing heart in vivo (n  7) was used. The effects of the reshaping device
on left ventricular performance were assessed by the slopes (Ees) of the left
ventricular end-systolic pressure-volume relations, hemodynamics, and echocardio-
graph before and after placing the CardioClasp on the heart. The change in Ees as
the result of left ventricular reshaping was also estimated from computed theoretical
analysis and compared with empirical data.
Results: There was a significant change in left ventricular dimension after placing
the CardioClasp on the heart. In isolated heart preparation, Ees significantly in-
creased from 1.40  0.44 mm Hg/mL to 2.42  0.63 mm Hg/mL after placing the
device on the heart but returned to the baseline level (1.46  0.27 mm Hg) after
removing it. Left ventricular developed pressure and left ventricular fractional area
shortening were significantly increased as the result of left ventricular reshaping.
Ees derived from computed theoretical analysis was highly correlated with con-
firming empirical data.
Conclusions: The CardioClasp can reshape the left ventricle and improve left
ventricular systolic performance in failing hearts.
Despite improved therapies to enhance survival, chronic heart fail-ure (CHF) continues to be an unsolved dilemma and challenge forthe medical community. Throughout disease progression, ventric-ular remodeling plays a vital role. One profound feature of re-modeling is that the left ventricular (LV) chamber becomes di-lated. As the LV dilates, the radius of curvature increases, placing
an extra “load” on the myocytes. Consistent with Laplace’s law, this results in an
increase in LV wall tension and a decrease in systolic function.1,2 Pharmacologic
approaches have greatly improved the management of CHF; however, the side
effects of pharmacologic therapy are always of concern and unavoidable.
Surgical procedures as therapies for improving LV size and function have been
reported3-5 with controversial outcomes. Batista and colleagues3 described the
partial left ventriculectomy for dilated cardiomyopathy, but many patients under-
going this procedure subsequently demonstrated ventricular arrhythmia, worsening
ventricular pump function, and even death.6-8 Novel implantable devices also have
been developed for the treatment of CHF. For instance, the LV assist device
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currently acts as a life-preserving bridge for patients with
end-stage heart failure until they receive a donor heart.9,10
Unfortunately, this treatment not only requires well-trained
surgeons and physicians, as well as high expenses, but also
carries the dangers of infection and thromboembolism.
LV reshaping exists as another option to correct the
geometric burden of the dilated LV. This type of therapy
rests on the hypothesis that reducing the radius of curvature
directly decreases the tension on myocardial cells; thus,
reducing the chamber’s radius would improve systolic ven-
tricular function. By using an LV-reshaping device, Mc-
Carthy and colleagues11 reported reduced LV wall stress
and improved LV systolic function in a canine model of
rapid cardiac pacing-induced heart failure. Our preliminary
study also showed improved LV systolic performance after
LV chamber reshaping in a failing heart.12,13 A small clin-
ical study showed that this type of device seems to be safe.14
However, the impacts of such therapies on cardiac mechan-
ics and their underlying physiology have not been system-
atically studied.
In this study, we tested the CardioClasp (CardioClasp
Inc, Pine Brook, NJ), a device that uses 2 external structural
elements to geometrically reshape the LV into 2 widely
communicating “lobes” of reduced radius (Figure 1, A). An
ex vivo isolated failing heart preparation was used in our
initial study, and those empirical results were further con-
firmed by our observations in failing canine hearts in vivo.
We developed a theoretical analysis to predict the effects of
LV reshaping on a diffusely hypocontractile and dilated LV.
The correlation between the predicted and the observed
alterations in LV pressure-volume relationship and the ac-
curacy of the computational analysis, both systolic and
diastolic elastance constants, were examined.
Methods
Seventeen adult mongrel dogs (7 dogs for in vivo experiments, 5
dogs for isolated heart experiments, and 5 dogs for hemodynamic
support of the isolated heart experiments) weighing between 25
and 32 kg were used for these studies. All animals received proper
and humane care in compliance with the Guide for the Care and
Use of Laboratory Animals, published by the National Institutes of
Health (NIH publication no. 85-23, revised 1985). This study was
approved by the Institutional Animal Care and Use Committee of
Columbia University.
The Induction of Chronic Heart Failure
A rapid cardiac pacing regimen resulting in CHF was used as
described previously.15,16 The dogs were chronically instrumented
for measurements of systemic hemodynamics and rapid cardiac
pacing. Approximately 7 days after the surgery, a baseline hemo-
dynamic assessment was performed while the dogs were in an
awake state. Then, rapid ventricular pacing was started. The LV
was paced at 210 beats/min for the first 3 weeks and then at 240
beats/min for the fourth week. After 4 weeks of the rapid cardiac
pacing, measurements of the resting hemodynamics were repeated
at least 40 minutes after turning off the pacer.16 The animals were
divided into 2 experimental groups: (1) acute in vivo intact heart
and (2) isolated heart preparation.
Figure 1. A, Schematic of the CardioClasp (CardioClasp Inc, Pine Brook, NJ). The device consists of 2 external
structural elements to geometrically reshape the left ventricular (LV) chamber. B, Structures of the CardioClasp
device and its placement on a heart.
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In Vivo Preparation and Experimental Protocol
Seven dogs were used to test the effects of the CardioClasp in
vivo. Once a stable CHF state was established and baseline
CHF hemodynamic assessments were made, a thoracotomy was
performed at the fifth costal space to explore the heart. An
ultrasonic flow probe (Transonic Systems, Ithaca, NY) was
placed around the root of the ascending aorta to continuously
measure cardiac output. A direct epicardial cross-sectional
echocardiographic image of the LV at end-diastole was ob-
tained. The anterior-posterior and septal-to-free wall distances
were measured. The CardioClasp was placed, reducing the
anterior-posterior LV end-diastolic dimension by approxi-
mately 30%; then, the direct epicardial echocardiography was
repeated. LV end-diastolic pressure (LVEDP) and cardiac out-
put were also measured with the device on and off.
Isolated Heart Preparation (Ex Vivo Study) and
Experimental Protocol
To test the effects of the passive LV-reshaping device, Cardio-
Clasp, on LV systolic properties, 5 isolated cross-perfused canine
hearts were studied by methods similar to those described previ-
ously17,18 and shown schematically in Figure 2. In brief, 2 dogs
were anesthetized with 30 mg/kg of intravenous pentobarbital
sodium. The femoral arteries and veins of 1 dog (“support dog”)
were cannulated and connected to a perfusion system used to
supply oxygenated blood to the isolated heart. The second dog
Figure 2. Schematic of isolated canine heart preparation showing donor heart perfused by blood from a “support”
dog.
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(“heart donor dog”) was mechanically ventilated, and a midline
sternotomy was performed. The heart was removed while being
metabolically supported by the arterial flow from the support dog.
The left and right atria were opened, and all the chordae tendineae
were freed from the leaflets of both mitral and tricuspid valves.
The isolated heart was then held by 2 metal adapters sutured to the
mitral and tricuspid valve rings. These adapters connected the
valve rings to a syringe system, which measured and controlled LV
volume by a water-filled balloon placed inside the LV chamber.
Within the balloon, a Millar pressure transducer (Millar Instru-
ments, Inc, Houston, Texas) was placed to measure ventricular
pressures. A heat exchanger maintained the perfusate temperature
at 37°C. The heart was atrially paced 10 to 15 beats/min greater
than the spontaneous rate, and the coronary arterial pressure was
set to approximately 100 mm Hg.
A baseline, cross-sectional echocardiographic image of the LV
at end-diastole was obtained, and the anterior-posterior and septal-
to-free wall distances were measured. The experiments examined
the effects of the CardioClasp on the end-systolic pressure-volume
relationship (ESPVR) in isovolumically contracting condition.
Two different interventions were performed: baseline and with the
CardioClasp on the heart. At baseline, a cross-sectional echo-
graphic image of the LV was obtained at end-diastole. From this
image, the anterior-posterior and septal-to-free wall distances were
measured. LV pressure-volume relationships (LV loops) were
obtained by continuously recording LV pressure while withdraw-
ing fluid from the ventricular balloon once the heart was beating.
A syringe pump was used for fluid withdrawal. The volume within
the balloon did not change during the course of each beat (iso-
volumic contraction): The pressure-volume relationship for that 1
beat was a single vertical trace. The pressure was read from the
intra-balloon Millar pressure transducer, and the volume was read
from the known balloon content. By gradually withdrawing fluid
from the balloon, a series of such straight traces can be generated.
The upper ends of the traces defined the ESPVR, and the lower end
of the traces presented the end-diastolic pressure-volume relation-
ship (EDPVR). After baseline measurements were obtained, the
CardioClasp device was positioned on the heart and adjusted to
reduce the average anterior-posterior LV end-diastolic dimension
by approximately 30%. The previously mentioned echocardio-
graphic measurements and LV pressure-volume relationship con-
structive procedures were repeated with the device in place. LV
pressure was also recorded during a rapid removal of the Cardio-
Clasp.
CardioClasp Device and Its Placement
The CardioClasp is composed of 2 rigid bars of fixed length and
curvature (Figure 1, B). These bars control the position of pivoting,
flexible, epicardial contacting pads. The device, which has no
blood-contacting elements, is positioned entirely around the left
heart in between the pulmonary veins and behind the ascending
aorta and pulmonary artery. The bars are connected by 2 flexible
tethers that are adjusted to approximate the opposite walls of the
LV and achieve the desired chamber radius reduction.
Variations in heart length are addressed by choice of Car-
dioClasp size. Canine length variation has been accommodated
by a choice of 3 discrete lengths. The choice of size was made
by a direct measurement of the distance from the roof of the left
atrium to the ventricular apex using a malleable wire measure-
ment tool. The desired degree of reshaping was addressed for
any chosen CardioClasp size by adjusting the distances between
the bar ends.
A cross-sectional echocardiographic image of the LV before
and after application of the device was obtained. The papillary
muscles were used as internal landmarks to compare images. The
distance of anterior-posterior wall (internal chamber endocardial
measurement) and wall thickness were measured by using an
end-diastolic image. The anterior-posterior diameter approxi-
mately corresponded to the plane in which the CardioClasp was
applied. The tethers were shortened to obtain a reduction of this
diameter of approximately 30%.
Data Collection
From the LV pressure-volume relationship, linear regression from
the points of maximal ratio between pressure and volume (top left
corner of each loop) provided the slope and volume axis intercept
to define the ESPVR. The slope (Ees) of the ESPVR presented the
contractile function of the LV. Similarly, the EDPVR was derived
by connecting the lower right corner of each loop.
Echocardiography measurements at rest were used for dimen-
sional measurements (eg, diameter and area) of the LV during
systole and diastole. LV area was determined by carefully tracing
the endocardial surface and integrating the area. Mean area ejec-
tion fraction (percent) was obtained from the equation: (mean
end-diastolic area  mean end-systolic area)/mean end-diastolic
area, by averaging at least 5 steady-state cardiac cycles.
Theoretical Analysis of Elastance Constant
LV pressure-volume relationship can be described by the equa-
tions Pes  Ees (Ves V0) and Ped  A (ek[Ved-Vo]  1). (Pes:
end-systolic pressure; Ped: end-diastolic pressure; V0: 0 pressure
volume; Ees, A, K: constants). On the basis of these equations, we
hypothesized that intrinsic time-varying LV wall circumferen-
tial length and tension relationships held true, and that longi-
tudinal changes were relatively minor, so the resulting new LV
ESPVRs and EDPVRs could be estimated from the geometri-
cally induced changes in the LV pressure-volume relationship.
From these, we theoretically projected a new EDPVR and Ees
(elastance constant and the index of LV contractile function)
based on new constant values for an approximately 32% radius-
reduced ventricle to match isolated heart experiments according
to our hypothesis. Then we experimentally examined the con-
stants V0, Ees, A, and K by matching curves in our isolated
TABLE 1. Baseline hemodynamics in awake state
Control Heart failure
LV systolic pressure (mm Hg) 144.3 8.8 112 6.0*
LV end-diastolic pressure (mm Hg) 9.1 2.0 29.6 4.0*
LV dP/dt (mm Hg/s) 3192 376 1578 118*
MAP (mm Hg) 107 6.2 89.5 6.1*
Heart rate (beats/min) 100 12 141 30*
LV, Left ventricle; MAP, mean arterial pressure.
*P  .05 from control.
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isovolumically contracting failing canine heart preparation (n 
4). The experimental curves of LV pressure-volume relation-
ships from these hearts were generated after a 32%  7% radius
reduction by the CardioClasp. Experimental and theoretical
values were compared, and the correlation between these 2 sets
of data was examined to test the hypothesis underlying expec-
tations for device-based ventricular reshaping. Detailed com-
putational methods are described in the Appendix and have
been described by Melvin.19
Statistical Analysis
The results are presented as means  standard deviation. Multiple
linear regression analysis with Bonferroni’s correction was used to
test for statistical significance of differences between linear rela-
tions with the CardioClasp on and off. Two-way analysis of
variance was used for comparisons of hemodynamic parameters,
Ees, and echocardiography parameters in different conditions.
Results
In Vivo Study
After 4 weeks of rapid cardiac pacing, severe heart failure
developed, as evidenced by significantly elevated LVEDP
and decreased LV dP/dt. Resting hemodynamic parameters
measured in the awake state are summarized in Table 1.
Our results showed that once the CardioClasp was placed
on the heart in an anesthetized state, there was a significant
change in the LV dimension. Figure 3 illustrates an echo-
cardiogram indicating the geometrical changes in LV shape.
In this case, there was an approximately 35% reduction in
the short axis of the LV, and the bi-lobular appearance of
the heart is clearly seen. In our group data, there was a 32%
 7% reduction in LV short axis. The impacts of such
reduction in LV dimension resulting from the placement of
the CardioClasp on LV systolic and diastolic properties in
vivo are shown in Table 2. LV end-diastolic area was
significantly reduced, and area ejection fraction was signif-
icantly increased with the device on. Cardiac output and
LVEDP were not changed. The difference in LVEDP during
the heart failure state, as shown in Tables 1 and 2, was the
Figure 3. An echocardiograph obtained from an intact animal, indicating a significant “reshaping” of the LV once
the CardioClasp was placed on the heart. In this case, there was an approximately 35% reduction in the short axis
of the LV, and the bi-lobe appearance of the heart is clearly seen.
TABLE 2. Impact of CardioClasp (CardioClasp Inc., Pine-
Brook, NJ) on left ventricle systolic and diastolic proper-
ties in vivo
Baseline CardioClasp on
LV end-diastolic area (cm) 12.0 0.9 10.4 1.3*
Area ejection fraction (%) 0.12 0.02 0.26 0.03*
Cardiac output (L/min) 2.2 0.4 2.0 0.4
LVEDP (mm Hg) 17.4 2.8 16.4 2.0
LVEDP, LV end-diastolic pressure.
*P  .05 from baseline (CardioClasp off).
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result of measurements taken in different conditions: awake
state versus anesthetized state and chest open.
Isolated Heart Study
The impacts of CardioClasp on LV performance were fur-
ther examined in isolated heart preparations. Figure 4 shows
an echocardiograph image from an isolated heart prepara-
tion, illustrating the impact of the device on the short axis
diameter (25% reduction in this case) and the reduction in
radii of curvature of the anterior and posterior “lobes” of the
heart. There was a 32%  7% reduction in the short axis
diameter of LV. ESPVRs and EDPVRs were constructed
using peak and minimum pressure during each cardiac cycle
while fluid was gradually withdrawn from the intraventric-
ular balloon. In the baseline condition (without the device),
there was a linear relationship between end-systolic pres-
sure and LV volume with a nonlinear EDPVR (Figure 5).
The placement of the CardioClasp resulted in a shift toward
lower volumes of both relationships. We noted that the
original linear relationship of ESPVR could be accurately
described by 2 linear relationships once the device was
placed on the heart. Figure 5 demonstrates the changes of
ESPVR and EDPVR curves resulting from the placement of
the device: A “breakpoint” divided the ESPVR curve into 2
regions. Below the breakpoint volume, the ESPVR slope
was basically the same as without the device, although it
was shifted toward lower volume. Above the breakpoint, the
ESPVR slope increased from the baseline condition, indi-
cating a positive influence of the device on LV contractile
strength. EDPVR was not significantly altered by LV re-
shaping. The changes in Ees (the slope of the ESPVR) are
summarized in Figure 6. After CardioClasp placement, Ees
significantly increased above the breakpoint, whereas Ees
did not change below the breakpoint. After removing the
device, Ees returned to the baseline level. The explanation
for the difference of Ees above and below the breakpoint is
as follows: The starling curve was defined by the relation-
ship between LV isovolumic development pressure and
end-diastolic pressure. There was no change in this relation-
ship below a certain point because the device was simply
uncoupled with the heart. The breakpoint was determined
from the Starling curve using the downhill simplex algo-
rithm20 (see Appendix). On average, the LV volume was 57
 7 mL, and the LV end-systolic pressure was 13.6  0.3
mm Hg at the breakpoint volume in our study. During the
experiment, we observed that the device was not able to
reshape the heart effectively once LV volume was below the
breakpoint.
An actual LV pressure response to a rapid removal of the
CardioClasp is illustrated in Figure 7. Both systolic and
diastolic LV pressures decreased. However, the decrease in
systolic pressure was greater than the decrease in LV dia-
stolic pressure, and there was a slight but significant in-
crease in LV developed pressure (LVDP), indicating that
the LV generated more force once the device was placed on
the heart. Table 3 summarizes the impacts of rapid removal
of the CardioClasp on LVDP.
Figure 4. An echocardiograph image from an isolated heart illustrates the impact of the device on the short axis
diameter and the elongation of the heart with reduction of radius of curvatures of the anterior and posterior “lobes”
of the heart.
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Theoretical Analysis of Left Ventricle Reshaping
Efficacy and Correlation With Empirical Data
The computed and empirical LVEDP and Ees are summa-
rized in Table 4. The 2 sets of data represent when LV
end-diastolic volume was sufficiently incrementally in-
creased to vary the LVEDP from 12 to 20 mm Hg. There
were significant increases in Ees of both theoretical and
experimental observed values from baseline (shape-unal-
tered LV). Notably, there was a very close correlation in
experimental observed and theoretical LV EDPVRs and
Ees. Theoretical predictions, for both ESPVRs and ED-
PVRs, were grounded in the assumptions that (1) although
stress-strain (or tension-length) relationships are intrinsic
and not likely to acutely change, (2) both pressure-stress and
strain-volume relationships are directly dependent on geom-
etry and would change immediately (and in a quite precise,
mathematically predictable fashion) with reshaping.
Observed behavior, both systolic and diastolic, was strik-
ingly similar to that predicted. The experimental and pre-
dicted EDPVRs were almost identical, as is apparent in
Table 4, with 0.97 to 0.99 coefficients of correlation in the
pressure range in which there were experimental and control
data. The Ees was 1.40 mm Hg/mL at baseline and was
predicted from theory to increase to 2.42 with LV reshap-
ing. It was experimentally observed to rise to a very similar
value, well within the accepted error range of our instru-
mentation (2.35).
Discussion
The relationship between LV chamber diameter and LV
wall stress can be described by Laplace’s law. According to
Laplace’s law, when the failing heart becomes dilated, an
extra load is placed on the myocardium because of the
increased radius of curvature of the LV. If the radius of
curvatures could be reduced, then the tension on the myo-
cardium would be decreased (even with no change in cavity
pressure), and LV systolic function could be improved.
Therefore, Laplace’s law has been cited as one of the major
physical principles explaining the potential benefits of vol-
ume-reduction strategy. Several LV volume-reduction ther-
apies have been introduced to clinical practice, such as the
procedure of Batista and colleagues,3 the endoventricular
circular patch plasty described by Dor and colleagues,4,5
and a number of other forms of ventricular aneurysmorrha-
phy.21,22 However, the uses of these surgical therapies are
very limited because of poor clinical benefits, such as in the
Batista procedure,6,23,24 or non-applicability to the com-
Figure 5. LV end-systolic pressure-volume relationship (ESPVR)
and end-diastolic pressure-volume relationship (EDPVR) before
(blue lines) and after (red and black lines) placement of the
CardioClasp. Under baseline conditions (before the LV-reshaping
device), there was an approximately linear relationship between
LV end-systolic pressure and LV volume with a nonlinear EDPVR.
CardioClasp placement resulted in a shift toward lower volumes
of both relationships. It was noted that the originally linear
relationship of ESPVR could be accurately described by 2 linear
relationships with a breakpoint dividing the 2 regions of the
curves. Below the breakpoint volume, the ESPVR slope was
basically the same as under baseline conditions, although it
shifted toward lower volumes. Above the breakpoint, the ESPVR
slope (Ees) increased (red dot line) from baseline (blue dot line),
indicating an influence of the device on LV contractile strength.
EDPVR was not significantly changed by placement of the Car-
dioClasp (CardioClasp on:  clasp).
Figure 6. Ees, the slope of the ESPVR, was 1.4  0.44 mm Hg/mL
at control. After CardioClasp placement, Ees increased to 2.4 
0.63 mm Hg/mL above the breakpoint (LVV > VBP), whereas Ees
below the breakpoint (LVV < VBP) was not changed by Cardio-
Clasp placement. After removing the device, Ees returned to the
baseline level (Re-control), 1.46  0.27 mm Hg/mL (*P < .01).
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monly occurring diffusely dilated ventricle, such as in the
Dor procedure.23
Another option is device-based remodeling of LV. By
this strategy, the LV is reshaped from a single ellipsoid into
2 widely communicating ventricular “lobes,” each lobe with
reduced radius. Notably, the objectives of reduction in LV
radius and, consequently, reduction in wall stress can be
achieved in this way without sacrificing myocardium and
loss of circumferential length of LV. A recent study by
McCarthy and colleagues11 demonstrated that such a device
improved LV ejection fraction and reduced both LV end-
systolic volume and end-systolic wall stress in pacing-
induced canine heart failure. Although the device used in
our study is different from the one used in McCarthy and
colleagues’ experiment, and our device consists of 2 indent-
ing bars (therefore reshaping the LV by the surface of the
heart without entering the LV chamber), the basic working
principle of these two devices is the same.
In the present study, we clearly showed the effectiveness
of the device to modify the geometry of LV in both isolated
heart preparation and acute in vivo experiments. The phys-
iologic impacts of the device on the ventricular mechanical
properties of failing hearts were examined in a well-docu-
mented isolated heart preparation. The load-independent
and heart rate-independent index of LV contractile function,
ESPVR (Ees), was used to assess any alterations of LV
systolic performance once the device was placed on a fail-
ing heart, resulting in changed geometry of LV in the
conditions of fixed LV volume. The ESPVR relationship
was clearly shifted to the left and to a higher level by the
placement of the device on a failing heart if LV volume was
higher than approximately 57 mL, correlating with end-
systolic pressures of approximately 13 to 14 mm Hg. We
also demonstrated a significant increase in LVDP once the
LV reshaping device was placed on the heart. This result
provided additional evidence of improved LV systolic per-
formance as the result of the device-reshaped LV. Because
all other variables were well controlled in our isolated heart
preparation, the positive effects of CardioClasp on LV sys-
tolic function, indicated by a leftward shift of LV pressure-
volume relationship, increased Ees, and increased LVDP,
were clearly demonstrated. This conclusion was further
supported by the results of echocardiography measurements
from in vivo experiments. Once the CardioClasp was placed
on a failing heart in vivo, area ejection fraction was signif-
icantly increased, whereas LVEDP and cardiac output were
not significantly altered. This is an important observation,
because it implies that if the LV radius is properly reshaped,
beneficial effects on LV systolic function can be obtained in
an intact heart. Our results are consistent with reports by
Mueller and colleagues25,26 stating that hemodynamic ben-
efits of LV reshaping were observed in bovine hearts with
increased central venous pressure.
This type of correlation between theoretically predicted
and experimentally observed behavior provides what is
probably the only practical test of the 3 underlying assump-
tions supporting the hypothesis regarding the functional
effects of device-based ventricular reshaping. A strain-in-
cremental volume relationship should, of course, be mea-
surable. Although the other 2 assumptions (effect of radius
change on wall stress and the lack of an effect of that change
on stress-strain relationship) may both be rather intuitive,
directly confirming either would require consistent, accu-
rate, and direct measurement of stress. No generally ac-
cepted means of performing that exists. Certainly, there may
be alternative explanations for the findings, but none is
readily apparent. We believe that the extremely close cor-
relation of predicted with observed effects on both the
quasi-linear end-systolic and near-exponential end-diastolic
elastance curves strongly indicates that the hypothesis is
indeed true. Because these predicted changes in elastance
are the foundation for expected hemodynamic benefits, their
experimental confirmation has substantial clinical implica-
tions.
In summary, by use of both isolated failing heart prepa-
ration and intact failing heart in vivo, we clearly demon-
Figure 7. A typical LV pressure response to a rapid removal of the
CardioClasp. Both LV systolic and diastolic pressures decreased.
However, the decrease in systolic pressure was greater than the
decrease in LV diastolic pressure, indicating a slight but signif-
icant increase in LV development pressure (LV development pres-
sure: vertical line with 2 arrows).
TABLE 3. Left ventricle systolic pressure and left ventricle
end-diastolic pressure responses to rapid removal of the
CardioClasp
LV Pressure (mm Hg)
Systolic Diastolic Developed
CardioClasp off 92 5* 24 2 68 4
CardioClasp on 114 6* 37 3* 77 6*
Difference 22 3 13 2 9 1
*P  .05 from CardioClasp off.
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strated that the LV-reshaping device CardioClasp was able
to efficiently reduce LV radius and remodel the geometric
shape of LV chamber acutely. An immediate improved LV
systolic performance was indicated by increased Ees,
LVDP, and area ejection fraction once the LV reshaping
device was placed on a failing heart. Computed theoretical
analysis of reshaping efficacy (LV EDPVR and Ees) was
highly correlated with confirming empirical data. This result
further supports our conclusion of an improved LV contrac-
tile function as the result of reducing LV radius. However,
further studies to confirm the long-term impact of this
device on CHF and LV remodeling are warranted.
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Appendix
Methods Used in Computational Analysis
New values for Ees, V0, A, and k, describing the new pressure-
volume relationships, were derived on the basis of the central
hypothesis of device reshaping (ie, the time-varying circumferen-
tial tension-length relationship is unchanged, whereas pressure-
tension and length-volume relationships are geometrically predict-
able) and the assumption that the reshaping would minimally
affect longitudinal behavior. For a fixed separation of reshaping
members (eg, CardioClasp bars or Myosplint buttons [Myocor,
Inc, Maple Grove, Minn]), the actual degree of radius reduction
varies slightly through ejection and refilling. Consequently, these
values are no longer truly “constants,” because they will change
slightly as the result of competing (although not fully canceling)
effects of baseline radius reduction and wall thickening during
contraction (and the reverse in relaxation).
The volume was calculated by modeling the LV cavity as 100
transverse slices. The area of each slice was computed by the
addition of component areas, holding the internal circumference of
that particular slice to be unchanged from the pre-reshaping state.
Bar geometry was predetermined (Figure 1, A) with “g,” the
transverse radius of curvature being 70 mm and bar-width suffi-
cient (18 mm) to allow tangential bar-epicardial parting and an
epicardial-cavity pressure ratio no greater than 1.4 with the range
of reshaping induced. Thus, the contact arc  was readily derived,
and the remainder of the geometric parameters, and slice area,
immediately followed. For the greatest radius reduction induced in
these studies (32%), this calculation yielded a volume reduction of
approximately 12%.
For example, during systole, Ees describes the ESPVR. This
can be considered, as can the EDPVR, to be the product of
pressure-tension, tension-length, and length-volume relationships.
Pressure-tension relation is proportional to the instantaneous in-
ternal radius, and length-volume is proportional to the instanta-
neous cross-sectional area relationship (again, assuming longitu-
dinal contribution is negligibly affected). Thus, at any point during
ejection or refilling, the new Ees, or “Ees',” will be the baseline Ees
divided by the product of the new and old radius ratio and the new
and old area ratio.
Similarly, but with somewhat more involved mathematics, the
new V0 may be shown to equal the old one times the instantaneous
area ratio, the new A to be the old one divided by the instantaneous
radius ratio, and the new k to be the old one divided by the
instantaneous area ratio. Although these new values define the
instantaneous pressure-volume relationships through the cardiac
cycle, some of the customary intuitive definitions no longer apply.
For example, it is important to note that “V0” would now only
define the volume at 0 pressure if the proportional reshaping stayed
the same until the ventricle became that small. It does not: Al-
though proportional radius reduction varies surprisingly little in
physiologic pressure ranges, for most ventricles the tension mem-
bers holding the reshaping bars or buttons would be slack well
before 0 pressure, and the ventricle would again have a circular
cross-section. In addition, although the new Ees continues to define
the end-systolic pressure-volume slope, that slope changes as the
ventricle fills and empties, so that the ESPVR is no longer lin-
ear—it is concave upward and to the left.
These new “pseudoconstants” were computed at an arbitrary
“index state” (ventricular circumference and thickness equal to
that at baseline end-diastole with ventricular pressure of 25 mm
Hg) and at several hundred increments or decrements below and
above that circumference both in contraction and in relaxation.
Full mathematical equations and their derivations were pre-
sented at the Fourth Symposium of the Society for Cardiac Vol-
ume Reduction, February 17, 2002 in Osaka, Japan. The manu-
script of that presentation, by Drs Melvin, Burkhoff, and Wang, is
under review for the Journal of Cardiac Surgery.27
2. Calculation of the Breakpoint by Use of the
Downhill Simplex Algorithm
After placement of the CardioClasp, a breakpoint divided ESPVR
into 2 regions. The downhill simplex algorithm20 was used to
determine the breakpoint and ESPVRs above and below the break-
point. The root mean squared difference between predicted lines
and measured ESPVRs above and below the breakpoint can be
minimized. Briefly,
A. ESPVR above the breakpoint is described as follows:
LVP  Sabove ● LVV  Iabove (A)
Where Sabove and Iabove is slope and intercept of ESPVR above
the breakpoint, respectively.
B. LVP at the breakpoint (LVPB) is expressed as a function of
LVV (LVVB) at the breakpoint:
LVPB  Sabove ● LVVB  Iabove (B)
C. From equation (A) and (B), ESPVR below the breakpoint
can be described:
LVP  Sbelow(LVV  LVVB)  LVPB (LVV  LVVB
Where Sbelow is the slope of ESPVR below breakpoint.
Now, the optimized parameters of Sabove, Iabove, Sbelow, and
LVVB are obtained by the downhill simplex algorithm and the root
mean squared difference of ESPVR above (LVV  LVVB) and
below (LVV  LVVB) the breakpoint is minimized.
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